Encorafenib
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: braftovi, NVP-LGX818-NXA
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Encorafenib is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2018. DrugCentral lists 22 molecular targets, including RAF1, BRAF and LIMK1. Recorded indications include BRAF mutation-positive colorectal cancer, Metastatic malignant melanoma and Unresectable malignant melanoma with BRAF gene mutation.
- Approval status: onp (first approved 2018 by the FDA).
- Molecular targets: RAF1, BRAF, LIMK1 and PCYT1A (22 listed in DrugCentral).
- Indications: BRAF mutation-positive colorectal cancer, Metastatic malignant melanoma and Unresectable malignant melanoma with BRAF gene mutation.
- ATC code: L01EC03 (B-Raf serine-threonine kinase (BRAF) inhibitors).
- Molecular formula: C22H27ClFN7O4S; molecular weight 540.01 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- BRAF mutation-positive colorectal cancer
- Metastatic malignant melanoma
- Unresectable malignant melanoma with BRAF gene mutation
Mechanism & targets
Molecular targets (22)
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2019-01-08 | PMDA | — | Ono Pharmaceutical Co., Ltd. | Yes |
| 2018-06-27 | FDA | — | ARRAY BIOPHARMA INC | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01EC03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › B-Raf serine-threonine kinase (BRAF) inhibitors |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: HRAS, KRAS, NRAS · Actionable PGx
- EMA label: BRAF · Testing Required
- FDA label: BRAF · Testing Required
- FDA label: HRAS, KRAS, NRAS · Actionable PGx
- HCSC label: HRAS, KRAS, NRAS · Actionable PGx
- HCSC label: BRAF · Testing Required
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Serous retinal detachment | 1948.8 |
| Neoplasm progression | 837.0 |
| Death | 314.7 |
| Second primary malignancy | 256.8 |
| Serous retinopathy | 255.8 |
| Retinal detachment | 245.3 |
| Off label use | 199.3 |
| Pyrexia | 179.7 |
| Nausea | 155.4 |
| Melanocytic naevus | 147.2 |
| Vision blurred | 138.2 |
| Dermatitis acneiform | 137.3 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Encorafenib is on its molecule page.
| Molecular formula | C22H27ClFN7O4S |
|---|---|
| Molecular weight | 540.01 g/mol |
| CAS number | 1269440-17-6 |
| InChIKey | CMJCXYNUCSMDBY-ZDUSSCGKSA-N |
| PubChem CID | 50922675 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Encorafenib used for?
DrugCentral lists the following indications for Encorafenib: BRAF mutation-positive colorectal cancer, Metastatic malignant melanoma and Unresectable malignant melanoma with BRAF gene mutation.
How does Encorafenib work?
Its molecular targets in DrugCentral include RAF1 (inhibitor), BRAF (inhibitor), LIMK1 and PCYT1A.
When was Encorafenib first approved?
Encorafenib was first approved by the FDA in 2018.
What is the chemical formula of Encorafenib?
Encorafenib has the molecular formula C22H27ClFN7O4S and a molecular weight of 540.01 g/mol.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5289 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3301612 — compound record and bioactivity
- PubChem CID 50922675 — chemical identifiers
- DrugBank DB11718 — drug record
- FDA UNII 8L7891MRB6 — substance identity
- DailyMed: FDA labels for Encorafenib — current prescribing information (label search)
- UniProt P04049 (RAF1) — target protein
- UniProt P15056 (BRAF) — target protein
- UniProt P53667 (LIMK1) — target protein
- UniProt P49585 (PCYT1A) — target protein
- UniProt P53671 (LIMK2) — target protein
- UniProt P11802 (CDK4) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.